» Articles » PMID: 18219308

Prodrugs: Design and Clinical Applications

Overview
Specialty Pharmacology
Date 2008 Jan 26
PMID 18219308
Citations 404
Authors
Affiliations
Soon will be listed here.
Abstract

Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.

Citing Articles

Green Tea: Current Knowledge and Issues.

Radeva-Ilieva M, Stoeva S, Hvarchanova N, Georgiev K Foods. 2025; 14(5).

PMID: 40077449 PMC: 11899301. DOI: 10.3390/foods14050745.


Synthesis of Enantiostructured Triacylglycerol Prodrugs Constituting an Active Drug Located at Terminal -1 and -3 Positions of the Glycerol Backbone.

Jonsdottir L, Haraldsson G Molecules. 2025; 30(5).

PMID: 40076218 PMC: 11902219. DOI: 10.3390/molecules30050991.


Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors.

Luo M, Wang X, Yu G, Ji J, Li L, Song F Exp Hematol Oncol. 2025; 14(1):33.

PMID: 40057807 PMC: 11889805. DOI: 10.1186/s40164-025-00624-9.


Current Trends in Clinical Trials of Prodrugs.

Boreski D, Schmid V, Bosquesi P, Dos Santos J, Scarim C, Reshetnikov V Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006024 PMC: 11859331. DOI: 10.3390/ph18020210.


Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives.

Yadav V, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R Front Med (Lausanne). 2025; 12:1535682.

PMID: 39911864 PMC: 11794224. DOI: 10.3389/fmed.2025.1535682.